What are ADC's

Our services

ADC Review
is made possible by:


Study Title
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas (NCT01805037)

Trial description
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin, also known as SGN-035, and rituximab) is in patients with certain types of lymphoma.

This study is for patients who have a type of lymphoma that expresses a tumor marker called CD30 and/or a type that is associated with the Epstein-Barr virus (EBV-related lymphoma) and who have not yet received any treatment for their cancer, except for dose-reduction or discontinuation (stoppage) of medications used to prevent rejection of transplanted organs (for those patients who have undergone transplantation). This study is investigating the combination of brentuximab vedotin and rituximab as a first treatment for lymphoma patients.

This trial is sponsored by Seattle Genetics/ Northwestern University. [1]

Study Data

  • Condition: Lymphoma
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 33
  • Start: March 2013
  • Estimated Primary Completion: January 2016 (Final data collection date for primary outcome measure)
  • Last verified: April 2015

Study Schematic 

Screen Shot 2016-07-06 at 4.32.32 PM


Last Editorial review: July 6, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar